Parkman Healthcare Partners LLC Has $10.37 Million Position in Schrödinger, Inc. (NASDAQ:SDGR)

Parkman Healthcare Partners LLC lowered its position in Schrödinger, Inc. (NASDAQ:SDGR) by 22.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 559,105 shares of the company’s stock after selling 162,268 shares during the period. Schrödinger accounts for 1.3% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 24th largest holding. Parkman Healthcare Partners LLC owned about 0.77% of Schrödinger worth $10,371,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Rubric Capital Management LP increased its stake in Schrödinger by 213.5% in the second quarter. Rubric Capital Management LP now owns 3,130,000 shares of the company’s stock valued at $60,534,000 after purchasing an additional 2,131,724 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Schrödinger by 58.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company’s stock valued at $36,083,000 after buying an additional 717,059 shares in the last quarter. Millennium Management LLC raised its stake in Schrödinger by 2,868.8% during the 2nd quarter. Millennium Management LLC now owns 487,831 shares of the company’s stock worth $9,435,000 after buying an additional 471,399 shares during the period. Stephens Investment Management Group LLC lifted its holdings in Schrödinger by 39.6% during the third quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company’s stock worth $28,565,000 after acquiring an additional 436,789 shares in the last quarter. Finally, Algert Global LLC increased its stake in Schrödinger by 246.0% during the 2nd quarter. Algert Global LLC now owns 87,220 shares of the company’s stock worth $1,687,000 after purchasing an additional 62,010 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Schrödinger Price Performance

Shares of SDGR stock opened at $21.95 on Wednesday. Schrödinger, Inc. has a 1 year low of $16.67 and a 1 year high of $38.00. The company’s fifty day simple moving average is $18.91 and its two-hundred day simple moving average is $20.14. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -9.38 and a beta of 1.56.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $35.30 million during the quarter, compared to the consensus estimate of $41.25 million. During the same period in the previous year, the business earned ($0.86) earnings per share. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. Equities research analysts anticipate that Schrödinger, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

SDGR has been the subject of a number of analyst reports. BMO Capital Markets raised their target price on shares of Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Morgan Stanley dropped their target price on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 21st. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.90.

Insider Activity at Schrödinger

In other news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total value of $27,221.18. Following the transaction, the insider now owns 13,469 shares in the company, valued at approximately $239,478.82. This trade represents a 10.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is owned by insiders.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.